Calls Now Open

2024 ADDF-Harrington + 2025 Harrington Scholar-Innovator Programs

You've just added:

Home / News

News + Media

March 25, 2024

Targeting the chromatin binding of exportin-1 disrupts NFAT and T cell activation

Nature Chemical Biology, published March 25, 2024 Continue Reading

March 19, 2024

International Harrington Prize Awarded to Dr. Arlene Sharpe

2024 Harrington Prize for Innovation in Medicine Recognizes Pioneering Work in Immunology Continue Reading

February 08, 2024

The Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute to Support Promising New Drug Development Addressing the Biology of Aging Among People with Alzheimer’s Disease

Dr. Paul Tesar of Case Western Reserve University and Dr. Donald F. Weaver of University Health Network selected for their work targeting novel pathways in Alzheimer’s Continue Reading

February 06, 2024

Oxford-Harrington Rare Disease Centre Opens Call for Proposals

New Scholar Award Accelerates Novel Therapies for Rare Diseases Continue Reading

January 03, 2024

Jonathan Stamler, MD, Named Fellow of the 2023 National Academy of Inventors

Co-founder and president of Harrington Discovery Institute at University Hospitals receives highest professional distinction awarded solely to inventors Continue Reading

December 21, 2023

Allyx Therapeutics Lead Compound ALX-001 is Safe and Tolerable at Doses, Achieving Full Brain Target Engagement in Healthy Older Adults

The study showed that all doses of ALX-001 were well tolerated, up to and including levels high enough to achieve full brain target engagement, supporting the company’s plans to continue clinical development for the treatment of Alzheimer’s disease. Continue Reading

December 13, 2023

Harrington Family Honored: The Faces of Life-Saving New Medicines

The Harrington Family has been recognized in Cleveland Magazine's 2023 Faces of Cleveland as "The Faces of Life-Saving New Medicines" Continue Reading

December 08, 2023

Wisconsin scientists studying gene-editing tech to cure blindness

Similar technology is gaining regulatory approval to treat sickle cell disease and drawing research attention to treat a wide range of health concerns Continue Reading

December 05, 2023

An Enzyme that Selectively S-nitrosylates Proteins to Regulate Insulin Signaling

New cause of diabetes discovered, offering potential target for new classes of drugs to treat the disease Continue Reading

November 30, 2023

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Sol-Gel Technologies, a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, begun Phase 3 testing of SGT-610 for Gorlin syndrome with the first patient screened. Continue Reading

We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.